IN THE CLAIMS

38 (currently amended): A method for inhibiting bone metastases from prostate cancer in a patient having prostate cancer which comprises human comprising administering thereto to the patient a therapeutically effective amount of a compound of formula III

III,

or a pharmaceutically acceptable salt thereof.

- 39 (original): The method of Claim 38 wherein the bone metastases are osteoblastic.
- 42 (currently amended): The method of Claim 40 38 which additionally comprises administering an anticancer drug.
- 43 (original): The method of Claim 42 wherein the anticancer drug is selected from the group consisting of leuprolide, goserelin, bicalutamide, nilutamide, flutamide, vitamin D, vitamin D analogues, estrogen, estrogen analogues, prednisone, hydrocortisone, ketoconazole, cyproterone acetate, and progesterone.
- 44 (currently amended): The method of Claim $\frac{40}{38}$ which additionally comprises administering radiation.

- 45 (currently amended): The method of Claim 40 38 which additionally comprises administering at least one therapeutic agent which impedes net bone loss.
- 46 (original): The method of Claim 45 wherein the therapeutic agent is a bisphosphonate.
 - 56 (cancelled)
 - 59-64 (canceled)
- 65 (amended): A method for inhibiting metastatic growth from prostate cancer in a patient having prostate cancer which comprises human comprising administering thereto to the patient a therapeutically effective amount of a compound of formula III

III,

or a pharmaceutically acceptable salt thereof.

- 66 (original): The method of Claim 65 wherein the $\frac{1}{1}$ metastatic growth is osteoblastic $\frac{1}{1}$ metastatic growth.
- 67 (original): The method of Claim 65 which additionally comprises administering an anticancer drug.

68 (original): The method of Claim 67 wherein the anticancer drug is selected from the group consisting of leuprolide, goserelin, bicalutamide, nilutamide, flutamide, vitamin D, vitamin D analogues, estrogen, estrogen analogues, prednisone, hydrocortisone, ketoconazole, cyproterone acetate, and progesterone.

69 (original): The method of Claim 65 which additionally comprises administering radiation.

70 (original): The method of Claim 65 which additionally comprises administering at least one therapeutic agent which impedes net bone loss.

71 (original): The method of Claim 70 wherein the therapeutic agent is a bisphosphonate.

72 (new): A method for inhibiting osteoblastic bone metastases from prostate cancer in a human comprising administering thereto a therapeutically effective amount of a compound of formula III

III,

or a pharmaceutically acceptable salt thereof.

73 (new): The method of Claim 72 which additionally comprises administering an anticancer drug.

74 (new): The method of Claim 73 wherein the anticancer drug is selected from the group consisting of leuprolide, goserelin, bicalutamide, nilutamide, flutamide, vitamin D, vitamin D analogues, estrogen, estrogen analogues, prednisone, hydrocortisone, ketoconazole, cyproterone acetate, and progesterone.

75 (new): The method of Claim 72 which additionally comprises administering radiation.

76 (new): The method of Claim 72 which additionally comprises administering at least one therapeutic agent which impedes net bone loss.

77 (original): The method of Claim 76 wherein the therapeutic agent is a bisphosphonate.

78 (new): A method for inhibiting osteoblastic metastatic growth from prostate cancer in a human comprising administering thereto a therapeutically effective amount of a compound of formula III

III,

or a pharmaceutically acceptable salt thereof.

79 (new): The method of Claim 78 which additionally

comprises administering an anticancer drug.

80 (new): The method of Claim 79 wherein the anticancer drug is selected from the group consisting of leuprolide, goserelin, bicalutamide, nilutamide, flutamide, vitamin D, vitamin D analogues, estrogen, estrogen analogues, prednisone, hydrocortisone, ketoconazole, cyproterone acetate, and progesterone.

81 (new): The method of Claim 78 which additionally comprises administering radiation.

82 (new): The method of Claim 78 which additionally comprises administering at least one therapeutic agent which impedes net bone loss.

83 (original): The method of Claim 82 wherein the therapeutic agent is a bisphosphonate.

84 (new): A method for inhibiting bone metastases from prostate cancer in a human comprising administering thereto a therapeutically effective amount of the hydrochloride salt of a compound of formula III

85 (new): The method of Claim 84 wherein the bone

metastases are osteoblastic.

- 86 (new): The method of Claim 84 which additionally comprises administering an anticancer drug.
- 87 (new): The method of Claim 86 wherein the anticancer drug is selected from the group consisting of leuprolide, goserelin, bicalutamide, nilutamide, flutamide, vitamin D, vitamin D analogues, estrogen, estrogen analogues, prednisone, hydrocortisone, ketoconazole, cyproterone acetate, and progesterone.
- 88 (new): The method of Claim 84 which additionally comprises administering radiation.
- 89 (new): The method of Claim 84 which additionally comprises administering at least one therapeutic agent which impedes net bone loss.
- 90 (new): The method of Claim 89 wherein the therapeutic agent is a bisphosphonate.
- 91 (new): A method for inhibiting metastatic growth from prostate cancer in a human comprising administering thereto a therapeutically effective amount of the hydrochloride salt of a compound of formula III

- 92 (new): The method of Claim 91 wherein the metastatic growth is osteoblastic metastatic growth.
- 93 (new): The method of Claim 91 which additionally comprises administering an anticancer drug.
- 94 (new): The method of Claim 93 wherein the anticancer drug is selected from the group consisting of leuprolide, goserelin, bicalutamide, nilutamide, flutamide, vitamin D, vitamin D analogues, estrogen, estrogen analogues, prednisone, hydrocortisone, ketoconazole, cyproterone acetate, and progesterone.
- 95 (new): The method of Claim 91 which additionally comprises administering radiation.
- 96 (new): The method of Claim 91 which additionally comprises administering at least one therapeutic agent which impedes net bone loss.
- 97 (new): The method of Claim 96 wherein the therapeutic agent is a bisphosphonate.
- 98 (new): A method for inhibiting osteoblastic bone metastases from prostate cancer in a human comprising administering thereto a therapeutically effective amount of the hydrochloride salt of a compound of formula III

99 (new): The method of Claim 98 which additionally comprises administering an anticancer drug.

100 (new): The method of Claim 99 wherein the anticancer drug is selected from the group consisting of leuprolide, goserelin, bicalutamide, nilutamide, flutamide, vitamin D, vitamin D analogues, estrogen, estrogen analogues, prednisone, hydrocortisone, ketoconazole, cyproterone acetate, and progesterone.

101 (new): The method of Claim 98 which additionally comprises administering radiation.

102 (new): The method of Claim 98 which additionally comprises administering at least one therapeutic agent which impedes net bone loss.

103 (new): The method of Claim 102 wherein the therapeutic agent is a bisphosphonate.

104 (new): A method for inhibiting osteoblastic metastatic growth from prostate cancer in a human comprising administering thereto a therapeutically effective amount of the hydrochloride salt of a compound of formula III

III.

105 (new): The method of Claim 104 which additionally comprises administering an anticancer drug.

106 (new): The method of Claim 105 wherein the anticancer drug is selected from the group consisting of leuprolide, goserelin, bicalutamide, nilutamide, flutamide, vitamin D, vitamin D analogues, estrogen, estrogen analogues, prednisone, hydrocortisone, ketoconazole, cyproterone acetate, and progesterone.

107 (new): The method of Claim 104 which additionally comprises administering radiation.

108 (new): The method of Claim 104 which additionally comprises administering at least one therapeutic agent which impedes net bone loss.

109 (new): The method of Claim 108 wherein the therapeutic agent is a bisphosphonate.